Stocks and Investing
Stocks and Investing
Mon, March 18, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Reiterated (TRDA) at Strong Buy and Held Target at $20 on, Mar 18th, 2024
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "Entrada Therapeutics, Inc." (TRDA) at Strong Buy and Held Target at $20 on, Mar 18th, 2024.
Raghuram has made no other calls on TRDA in the last 4 months.
There is 1 other peer that has a rating on TRDA. Out of the 1 peers that are also analyzing TRDA, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Hartaj Singh of "Oppenheimer" Initiated at Buy and Held Target at $22 on, Friday, January 5th, 2024
Contributing Sources